NewsRelease
ResearchArticle Cites HemogloBind™ in Cancer Derived Exosome Study
MONMOUTHJUNCTION, NJ, January10, 2017 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their hemoglobin depletiontechnology for improving the signal from an exosome assay obtainedfrom hemolyzed mouse sera. The citation is:
Nishida-Aoki,Nao, et al. "Disruption of Circulating Extracellular Vesicles asa Novel Therapeutic Strategy against Cancer Metastasis."MolecularTherapy25.1 (2017): 181-191.
http://dx.doi.org/10.1016/j.ymthe.2016.10.009
Thisstudy considers that therapeutic strategies targeting cancer-derivedextracellular vesicles (EVs) hold great promise because of thepossibility they reposition microenvironments to accommodatemetastasis. The researchers report on a novel strategy of therapeuticantibody treatment to target cancer-derived EVs and inhibit themetastasis of breast cancer in a mouse model. The article states“Hemoglobin was accumulated with HemogloBind beads (Biotechsupport group, Monmouth Junction NJ, USA) followed by 0.22 μmfiltration. Then, the EVs in the sera were concentrated byultracentrifugation…”. The authors conclude thattherapeutic antibody administration effectively suppressesEV-triggered metastasis and that the elimination of cancer-exosomederived EVs could be a novel strategy for therapy.
“Iam very pleased that this article demonstrates the importance ofremoving hemoglobin from hemolyzed mouse sera, and that Hemoglobind™treatment significantly improved the signals of the exosome assay.The study demonstrates the importance of exosomes in cancerpathogenesis and suggests an exciting new therapeutic strategy”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866, [email protected]